At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,713 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
Nanjing First Hospital, Nanjing Medical University·observational·Posted Dec 5, 2017·Updated Apr 14, 2022
In Brief
An observational study for Type2 Diabetes. Completed, enrolled 1,713 participants.
Detailed Summary
Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType2 Diabetes
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
Primary CompletionAug 2016
Study CompletionJun 2017
First PostedDec 2017
TodayJul 2026
First PostedDec 5, 2017
Enrollment StartJan 30, 2015
Primary CompletionAug 31, 2016
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.6 years ago